Abstract
Background: Inflammation is a natural reaction of our body in response to infection or any other injury to renovate that damage. The majority of the available Non-steroidal anti-inflammatory drugs is nonselective and consequently, causes gastric irritation and ulceration. Therefore, it is a beard to design and synthesize a new series of Non-steroidal anti-inflammatory drugs with minimal gastric complications.
Methods: A series of novel 4-(3,4-dimethylphenyl)-2(1H)-phthalazinone derivatives were designed, synthesized and evaluated for their in vivo anti-inflammatory activity. The compounds that showed powerful anti-inflammatory activities were assessed for their in vitro COX-1/COX-2 inhibitory activity and their in vivo ulcerogenic profile. The interaction between the designated compounds and the binding pocket of the COX-2 enzyme was predicted by molecular docking stimulation.
Results: Six compounds, 2, 4, 5, 7a, 7b, and 8b showed significant anti-inflammatory activities at 4h compared to standard drug celecoxib. Compounds 4, 5, and 8b were the most potent and selective COX-2 inhibitors. Moreover, all the screened compounds demonstrated higher gastric safety profile compared to celecoxib particularly compound 8b displayed the highest safety profile. Among the tested compounds, 8b displayed the best fitting score, the highest antiinflammatory activity and COX-2 selectivity with minimal ulcer score.
Conclusion: A new series of phthalazinone derivatives were successfully synthesized and were evaluated for their in vivo anti-inflammatory activity. Six compounds (2, 4, 5, 7a, 7b, and 8b) presented powerful anti-inflammatory activity compared to celecoxib. Moreover, compounds 4, 5 and 8b were the most potent inhibitors to COX-2 and were inactive to COX-1. The screened compounds showed better ulcer protection and less gastric lesion compared to celecoxib. Compound 8b was the most promising candidate with more gastric safety.
Keywords: 4-Arylphthalazinones, anti-inflammatory, celecoxib, cyclooxygenase, COX-1/COX- inhibition assay, molecular docking, ulcerogenicity.
Graphical Abstract
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Novel 4- Aryl-2(1H)-phthalazinone Derivatives as Cyclooxygenase-2 Inhibitors: Synthesis, Molecular Modeling Study and Evaluation as Promising Anti-inflammatory Agents
Volume: 14 Issue: 3
Author(s): Sherifa Hasabelnaby, Eman M. Mohi El-Deen and Ayman Goudah
Affiliation:
Keywords: 4-Arylphthalazinones, anti-inflammatory, celecoxib, cyclooxygenase, COX-1/COX- inhibition assay, molecular docking, ulcerogenicity.
Abstract: Background: Inflammation is a natural reaction of our body in response to infection or any other injury to renovate that damage. The majority of the available Non-steroidal anti-inflammatory drugs is nonselective and consequently, causes gastric irritation and ulceration. Therefore, it is a beard to design and synthesize a new series of Non-steroidal anti-inflammatory drugs with minimal gastric complications.
Methods: A series of novel 4-(3,4-dimethylphenyl)-2(1H)-phthalazinone derivatives were designed, synthesized and evaluated for their in vivo anti-inflammatory activity. The compounds that showed powerful anti-inflammatory activities were assessed for their in vitro COX-1/COX-2 inhibitory activity and their in vivo ulcerogenic profile. The interaction between the designated compounds and the binding pocket of the COX-2 enzyme was predicted by molecular docking stimulation.
Results: Six compounds, 2, 4, 5, 7a, 7b, and 8b showed significant anti-inflammatory activities at 4h compared to standard drug celecoxib. Compounds 4, 5, and 8b were the most potent and selective COX-2 inhibitors. Moreover, all the screened compounds demonstrated higher gastric safety profile compared to celecoxib particularly compound 8b displayed the highest safety profile. Among the tested compounds, 8b displayed the best fitting score, the highest antiinflammatory activity and COX-2 selectivity with minimal ulcer score.
Conclusion: A new series of phthalazinone derivatives were successfully synthesized and were evaluated for their in vivo anti-inflammatory activity. Six compounds (2, 4, 5, 7a, 7b, and 8b) presented powerful anti-inflammatory activity compared to celecoxib. Moreover, compounds 4, 5 and 8b were the most potent inhibitors to COX-2 and were inactive to COX-1. The screened compounds showed better ulcer protection and less gastric lesion compared to celecoxib. Compound 8b was the most promising candidate with more gastric safety.
Export Options
About this article
Cite this article as:
Hasabelnaby Sherifa, M. Mohi El-Deen Eman and Goudah Ayman, Novel 4- Aryl-2(1H)-phthalazinone Derivatives as Cyclooxygenase-2 Inhibitors: Synthesis, Molecular Modeling Study and Evaluation as Promising Anti-inflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14 (3) . https://dx.doi.org/10.2174/1871523014666151103113544
DOI https://dx.doi.org/10.2174/1871523014666151103113544 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and ex vivo Study of the Vasorelaxant Activity Induced by Isosteric Derivatives of Dihydropyridines (NH→O)
Letters in Drug Design & Discovery The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process
Current Drug Metabolism The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism High-Resolution CT Imaging Findings of Collagen Vascular Disease- Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews Multifunctional Tacrine Derivatives in Alzheimer’s Disease
Current Topics in Medicinal Chemistry CD36 and Intestinal Fatty Acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Rosuvastatin Ameliorates Obesity and Proteinuria in Zucker Diabetic Fatty Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry Endothelial Dysfunction and Angiogenesis in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Desmopressin 30 Years in Clinical Use: A Safety Review
Current Drug Safety PET Tracers for Mapping Adenosine Receptors as Probes for Diagnosis of CNS Disorders
Central Nervous System Agents in Medicinal Chemistry